LRIG1、EGFR、E-Cadherin及N-Cadherin在胶质瘤中表达及其临床意义  被引量:9

Expression of LRIG1,EGFR,E-Cadherin and N-Cadherin in astrocytoma and their clinical significances

在线阅读下载全文

作  者:王鹏[1] 杨勇[2] 王景文[3] 胡昌龙[1] 袁志诚[2] 陆培松[2] 湛利平[2] 李巧玉[2] 

机构地区:[1]镇江市第一人民医院急诊外科,212002 [2]镇江市第一人民医院神经外科,212002 [3]江苏大学临床医学院

出  处:《临床神经外科杂志》2016年第2期118-121,126,共5页Journal of Clinical Neurosurgery

基  金:镇江市社会发展项目(SH2011035,SH2013050);江苏大学医学临床科技发展基金项目(JLY20140015)

摘  要:目的研究富含亮氨酸重复序列免疫球蛋白样蛋白1(LRIG1)、表皮生长因子受体(EGFR)、ECadherin及N-Cadherin在不同病理级别胶质瘤中表达差异,探讨LRIG1在胶质瘤恶性进展中可能的作用机制。方法收集74例胶质瘤患者手术标本,包含12对原发及复发配对胶质瘤标本,采用qRT-PCR检测LRIG1、EGFR、E-Cadherin、N-Cadherin基因的表达,并采用免疫印迹检测LRIG1、EGFR、E-Cadherin、NCadherin、Vimentin蛋白表达情况。结果随着胶质瘤病理级别的升高,LRIG1、E-Cadherin基因及蛋白表达水平降低,EGFR、N-Cadherin基因及蛋白表达水平升高,差异均具有统计学意义(均P<0.05)。WHOⅢ-Ⅳ组胶质瘤EGFR/LRIG1及N-Cadherin/E-Cadherin比值显著高于WHOⅠ-Ⅱ组(均P<0.05)。EGFR/LRIG1与NCadherin/E-Cadherin变化之间存在正相关(r=0.56,P<0.05)。对原发及复发配对胶质瘤标本的研究结果与上述一致。结论胶质瘤中EGFR/LRIG1表达失衡,可能通过诱导上皮间质转化(EMT)促进胶质瘤细胞的恶性进展。LRIG1可能成为胶质瘤治疗的新靶点。Objective To observe the expression of Leucine-rich repeats and immunoglobulin-like domains protein 1( LRIG1),epidermal growth factor receptor( EGFR),E-Cadherin and N-Cadherin in astrocytoma and explore the possible mechanism of glioma progression. Methods 74 astrocytoma surgical specimens,including 12 pairs of primary and recurrent specimens were studied. LRIG1,EGFR,E-Cadherin,N-Cadherin gene and protein expression were detected by qRT-PCR and Western Blotting respectively. Results LRIG1 and E-Cadherin gene and protein expression were higher,while EGFR and N-Cadherin expression were lower in the more malignant glioma samples( all P 0. 05). The ratio of EGFR / LRIG1 and N-Cadherin / E-Cadherin in WHO Ⅲ-Ⅳ group was significantly higher than that in WHO Ⅰ-Ⅱ group( all P 0. 05). EGFR / LRIG1 and N-Cadherin /E-Cadherin were positively correlated( r = 0. 56,P 0. 05). The study of primary and recurrent paired astrocytoma samples had similar findings as above. Conclusions Imbalance of EGFR /LRIG1 expression may promote glioma progression by inducing epithelial-mesenchymal transition of glioma cells. LRIG1 may become a new target for the treatment of glioma.

关 键 词:LRIG1 表皮生长因子受体 脑胶质瘤 上皮间质转化 

分 类 号:R739.41[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象